trending Market Intelligence /marketintelligence/en/news-insights/trending/kxcs_kg2mobttzx7vdh0cw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

XOMA sells rights to future royalty streams

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


XOMA sells rights to future royalty streams

HealthCare Royalty Partners II LP bought the rights to two of XOMA Corp.'s future royalty streams for $18 million up front, plus additional milestone-related payments totaling $4 million.

XOMA was eligible to receive royalty payments from each of Pfizer Inc. and Dyax Corp. after it licensed its technology to the companies.

HealthCare Royalty will pay $6.5 million in up-front payment for the Pfizer royalty payments and $11.5 million for the rights to the Dyax royalties.

HealthCare Royalty will also pay up to a further $4 million in milestone-related payments for the Pfizer royalty stream.

In other news, XOMA said it will repay $10 million it owes to Hercules Technology Growth Capital Inc. in exchange for releasing the security interest on the royalty agreements.